GILD · News · 20260825N

Regulatory Approval Milestones

GILEAD SCIENCES, INC. · 2026-08-25 · Importance 16 · Surprise 60

The European Commission approved a label expansion for Gilead Sciences’ Trodelvy in combination with Keytruda. The authorization permits first-line use in metastatic triple-negative breast cancer (TNBC) in the European Union. The decision expands Trodelvy’s eligible oncology population and supports Gilead’s oncology growth opportunity, although no financial impact or implementation timeframe was reported.